سعر جولينوساب 0.5مجم 2 قرص 2026

Cabergoline 0.5 mg tablets, pack of 2; Sabaa > SAB for Trading Import & Export (Egypt).

• Treatment of hyperprolactinemic disorders, idiopathic or due to pituitary adenomas, in adults. US labeling: avoid use for inhibition or suppression of postpartum physiologic lactation.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Inhibition of physiological lactation soon after delivery and suppression of established lactation (when the mother elects not to breastfeed or breastfeeding is contraindicated, after stillbirth or abortion); treatment of hyperprolactinaemic disorders.electronic medicines compendium (emc), UK

• Most common adverse reactions (>10%): nausea, headache and dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Uncontrolled hypertension; known hypersensitivity to ergot derivatives; history of cardiac valvular disorders or pericardial fibrosis; history of pleural, pulmonary or retroperitoneal fibrotic disorders.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to cabergoline, excipients or any ergot alkaloid; history of pulmonary, pericardial and retroperitoneal fibrotic disorders; hepatic insufficiency; toxaemia of pregnancy; co-administration with antipsychotics; history of puerperal psychosis; for long-term treatment, cardiac valvulopathy on pre-treatment echocardiography.International label, same formulation · electronic medicines compendium (emc), UK

• Cardiac valvulopathy and pericardial fibrosis: echocardiographic evaluation before treatment and every 6-12 months; discontinue if new valvular regurgitation/restriction, leaflet thickening or pericarditis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Pleural, pulmonary and retroperitoneal fibrosis; orthostatic hypotension (check blood pressure); impulse control disorders (gambling, sexual urges, spending) - consider dose reduction or stopping.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• US labeling: avoid use for inhibition or suppression of physiologic lactation; bromocriptine used this way was associated with hypertension, stroke, myocardial infarction, seizures and death.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Dopamine D2 antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide)Concomitant use not recommended.DailyMed (U.S. National Library of Medicine)

• If conception occurs during therapy, discontinue if risks to mother or fetus outweigh benefits; generally avoid dopamine agonists during pregnancy and postpartum (higher risk with pregnancy-induced hypertension, pre-eclampsia, eclampsia). Case reports have not shown a clear association with major birth defects.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No adequate well-controlled studies in pregnant women; in an observational study of 256 pregnancies 6.6% had major congenital malformations or abortion; it is not possible to determine whether risk is increased.International label, same formulation · electronic medicines compendium (emc), UK
• Not recommended in postpartum women who are breastfeeding or planning to breastfeed.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cabergoline: Ergot-derived dopamine receptor agonist with high affinity for D2 receptors; directly inhibits prolactin secretion by pituitary lactotrophs.